Achmea Investment Management B.V. Sells 14,550 Shares of Hologic, Inc. (NASDAQ:HOLX)

Achmea Investment Management B.V. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 40.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,647 shares of the medical equipment provider's stock after selling 14,550 shares during the period. Achmea Investment Management B.V.'s holdings in Hologic were worth $1,337,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HOLX. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Smithfield Trust Co grew its stake in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the period. Raiffeisen Bank International AG bought a new position in Hologic during the fourth quarter worth about $49,000. Finally, West Financial Advisors LLC purchased a new position in shares of Hologic in the first quarter worth about $50,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ:HOLX traded down $0.26 during trading on Wednesday, reaching $65.08. The company had a trading volume of 1,358,293 shares, compared to its average volume of 2,367,089. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $14.50 billion, a P/E ratio of 27.42, a price-to-earnings-growth ratio of 2.39 and a beta of 0.55. The company has a fifty day moving average of $60.31 and a two-hundred day moving average of $63.85.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the company posted $1.03 earnings per share. The company's revenue was down 1.2% compared to the same quarter last year. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director directly owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent research reports. Morgan Stanley reduced their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Raymond James Financial reiterated an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Citigroup decreased their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Evercore ISI reduced their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.